Literature DB >> 31095696

HighResNPS.com: An Online Crowd-Sourced HR-MS Database for Suspect and Non-targeted Screening of New Psychoactive Substances.

Marie Mardal1, Mette Findal Andreasen2, Christian Brinch Mollerup1, Peter Stockham3, Rasmus Telving2, Nikolaos S Thomaidis4, Konstantina S Diamanti4, Kristian Linnet1, Petur Weihe Dalsgaard1.   

Abstract

The number of new psychoactive substances (NPS) is constantly increasing. However, although the number might be large, most NPS have a low prevalence of use, so keeping screening libraries updated with the relevant analytical targets becomes a challenge. One way to ensure sufficient screening coverage is to use shared high resolution-mass spectrometry (HR-MS) databases, such as HighResNPS.com: a free, online, spreadsheet-format, crowd-sourced HR-MS database for NPS screening. The aims of this study were (i) to present the database to the scientific community and (ii) to verify that the HighResNPS database can be utilized in suspect screening workflows for LC-HR-MS instruments and software from four different instrument vendors. A sample was spiked with 10 NPS, and participating laboratories then analyzed the sample with their respective HR-MS vendor platforms and the HighResNPS database. The HighResNPS data were obtained via a spreadsheet converted to fit the import specifications of the different vendor platforms. Suspect screening was performed using LC-HR-MS vendor platforms from Thermo Fisher, Waters, Bruker and Agilent. All 10 NPS were identified in at least three workflows used for the four different vendor platforms. Multiple users have submitted data to HighResNPS for the same NPS, which resulted in multiple true-positive identifications for these NPS. Suspect screening with LC-HR-MS can be based on diagnostic fragment ions reported by users of different vendor platforms and can support NPS identification in biological samples and/or seizure analyses when no reference standard is available in-house. The present work clearly demonstrates that HighResNPS data is compatible with instruments and screening software from at least four different vendor platforms. The database can thus serve as a useful add-on in LC-HR-MS screening workflows.
© The Author(s) 2019. Published by Oxford University Press.

Entities:  

Year:  2019        PMID: 31095696     DOI: 10.1093/jat/bkz030

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  5 in total

1.  First identification, chemical analysis and pharmacological characterization of N-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2-benzylbenzimidazole opioid subclass.

Authors:  Marthe M Vandeputte; Nick Verougstraete; Donna Walther; Grant C Glatfelter; Jeroen Malfliet; Michael H Baumann; Alain G Verstraete; Christophe P Stove
Journal:  Arch Toxicol       Date:  2022-04-21       Impact factor: 6.168

2.  A New Strategy for Efficient Retrospective Data Analyses for Designer Benzodiazepines in Large LC-HRMS Datasets.

Authors:  Meiru Pan; Brian Schou Rasmussen; Petur Weihe Dalsgaard; Christian Brinch Mollerup; Marie Katrine Klose Nielsen; Michael Nedahl; Kristian Linnet; Marie Mardal
Journal:  Front Chem       Date:  2022-05-19       Impact factor: 5.545

3.  How to perform spectrum-based LC-HR-MS screening for more than 1,000 NPS with HighResNPS consensus fragment ions.

Authors:  Anders Davidsen; Marie Mardal; Kristian Linnet; Petur Weihe Dalsgaard
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

Review 4.  Developments in high-resolution mass spectrometric analyses of new psychoactive substances.

Authors:  Joshua Klingberg; Bethany Keen; Adam Cawley; Daniel Pasin; Shanlin Fu
Journal:  Arch Toxicol       Date:  2022-02-09       Impact factor: 5.153

5.  Identification of the synthetic cannabinoid-type new psychoactive substance, CH-PIACA, in seized material.

Authors:  Daniel Pasin; Michael Nedahl; Christian Brinch Mollerup; Christian Tortzen; Lotte Ask Reitzel; Petur Weihe Dalsgaard
Journal:  Drug Test Anal       Date:  2022-06-16       Impact factor: 3.234

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.